Microsaic Systems plc (LON: MSYS) CEO Glenn Tracey talks to DirectorsTalk about its Final Results for the year ended 31st Dec 2018. Glenn talks us through the achievements against what he’d set out to do, explains what’s difference from a couple of years ago, if a small foot-print means less performance, competing on a world stage and 2019 so far and what we can expect.
Microsaic Systems plc is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry (“MS”) instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company works with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.
The company’s compact MiD® MS systems retain the functionality of larger conventional MS systems, while being easier to use by non-specialists, and consume less energy and have lower running costs.